The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

SEK 31 million to enhance the effect of immunotherapy in the treatment of cancer patients

Illustration av T-cellsattack på cancercell. Illustration: iStock/luismmoling
Illustration of T cell attack on cancer cell. Illustration: iStock/luismmoling

Göran Jönsson, professor of molecular oncology, receives SEK 31 million from the Knut and Alice Wallenberg Foundation to enhance the effect of immunotherapy in the treatment of cancer patients.

About 30 per cent of patients with metastatic melanoma benefit from immunotherapy. At the same time, this means that 70 per cent of all melanoma patients still have no effective treatment option. Göran Jönsson and his colleagues want to identify new drugs for this patient group.

“It is a remarkably prestigious grant and we are very pleased. It means that together with my co-applicant, I now have the time and resources to pose the important questions concerning immunotherapy, tertiary lymphoid structures and melanoma cancer. We have many ideas and thoughts that we can now work on and develop in order to understand the fundamental mechanisms that explain why not all melanoma patients benefit from immunotherapy,” says Göran Jönsson.

Three more researchers at Lund University received project grants from the Knut and Alice Wallenberg Foundation Mikael Akke, Sara Linse and Michel Gisselbrecht at the Faculty of Science and Engineering. Read more here: Four Lund researchers receive SEK 120 million from the Knut and Alice Wallenberg Foundation

This year, the Knut and Alice Wallenberg Foundation is granting a total of SEK 700 million to 23 innovative basic research projects at Swedish higher education institutions.

Link to original article in Swedish published 14 October 2022

Göran B Jönsson

Co-applicants